Drug Profile


Alternative Names: SYL-040012

Latest Information Update: 19 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sylentis
  • Class Antiglaucomas; Small interfering RNA
  • Mechanism of Action Beta 2 adrenergic receptor antagonists; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glaucoma; Ocular hypertension

Most Recent Events

  • 02 Oct 2015 Interim efficacy and adverse events data from a phase IIb SYLTAG trial in Ocular hypertension released by Sylentis
  • 17 Aug 2015 Phase-II development is ongoing for Glaucoma and Ocular hypertension in Europe and USA
  • 17 Jul 2014 Sylentis initiates enrolment in a phase IIb trial for Glaucoma and Ocular hypertension in Estonia (EudraCT2013-002947-27)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top